Q32 Bio
NASDAQ: QTTBFounded 2017 · 6 known investors
Q32 Bio develops targeted immune therapeutics, with its lead candidate bempikibart (ADX-914), a fully human anti-IL-7Rα antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling. The company is advancing bempikibart in a Phase 2 program for patients with alopecia areata.
BiotechHealthtech
Investors · 6
Competitors · 5
by search overlapStocktwits26 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Seeking Alpha21 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Q Bio, Inc.19 shared keywordsQ.bio provides quantitative biology assessments and longitudinal health monitoring for preventive care, offering comprehensive measurable exams at the scale of premium care providers.
Qu Biologics19 shared keywordsQu Biologics develops treatments aimed at cancer, chronic inflammatory diseases, and metabolic diseases by restoring normal immune function. It operates in the biotech and immunotherapy space.
Robinhood17 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Q32 Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Q32 Bio do?
- Q32 Bio develops targeted immune therapeutics, with its lead candidate bempikibart (ADX-914), a fully human anti-IL-7Rα antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling. The company is advancing bempikibart in a Phase 2 program for patients with alopecia areata.
- Who are Q32 Bio's investors?
- Q32 Bio's investors include Atlas Venture, CU Healthcare Innovation Fund, OrbiMed, OUP (Osage University Partners), Sanofi Ventures, Agent Capital.